|
|
Blood, 15 January 2005, Vol. 105, No. 2, pp. 453-463.
Prepublished online as a Blood First Edition Paper on June 10, 2004; DOI 10.1182/blood-2003-12-4195.
 Previous Article | Table of Contents | Next Article 
REVIEW IN TRANSLATIONAL HEMATOLOGY
New anticoagulants
Jack Hirsh,
Martin O'Donnell, and
Jeffrey I. Weitz
From the Henderson Research Center and McMaster University, Hamilton, ON, Canada.
Abstract
Anticoagulants are pivotal agents for prevention and treatment of thromboembolic disorders. Limitations of existing anticoagulants, vitamin K antagonist and heparins, have led to the development of newer anticoagulant therapies. These anticoagulants have been designed to target specific coagulation enzymes or steps in the coagulation pathway. New anticoagulants that are under evaluation in clinical trials include: (1) inhibitors of the factor VIIa/tissue factor pathway; (2) factor Xa inhibitors, both indirect and direct; (3) activated protein C and soluble thrombomodulin; and (4) direct thrombin inhibitors. Although most of these are parenteral agents, several of the direct inhibitors of factor Xa and thrombin are orally active. Clinical development of these therapies often starts with studies in the prevention of venous thrombosis before evaluation for other indications, such as prevention of cardioembolism in patients with atrial fibrillation or prosthetic heart valves. At present, the greatest clinical need is for an oral anticoagulant to replace warfarin for long-term prevention and treatment of patients with venous and arterial thrombosis. Ximelagatran, an oral direct thrombin inhibitor, is the first of a series of promising new agents that might fulfill this need. Large phase 3 trials evaluating ximelagatran for the secondary prevention of venous thromboembolism and prevention of cardioembolic events in patients with atrial fibrillation have been completed.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Y. Koh, M. Kazimirova, A. Trimnell, P. Takac, M. Labuda, P. A. Nuttall, and R. M. Kini
Variegin, a Novel Fast and Tight Binding Thrombin Inhibitor from the Tropical Bont Tick
J. Biol. Chem.,
October 5, 2007;
282(40):
29101 - 29113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A.A. Fox, J.-P. Bassand, S. R. Mehta, L. Wallentin, P. Theroux, L. S. Piegas, V. Valentin, T. Moccetti, S. Chrolavicius, R. Afzal, et al.
Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non-ST-Segment Elevation Acute Coronary Syndromes
Ann Intern Med,
September 4, 2007;
147(5):
304 - 310.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hirsh, M. O'Donnell, and J. W. Eikelboom
Beyond Unfractionated Heparin and Warfarin: Current and Future Advances
Circulation,
July 31, 2007;
116(5):
552 - 560.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Asghar and P. Bowman
A clinical approach to the management of thrombosis in obstetrics. Part 2: diagnosis and treatment of venous thromboembolism
Obstet Gynaecol (Lond),
January 1, 2007;
9(1):
3 - 8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Rogers, J. A. Rebuck, and R. F. Sing
Venous Thromboembolism in Trauma: An Update for the Intensive Care Unit Practitioner
J Intensive Care Med,
January 1, 2007;
22(1):
26 - 37.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J.-J. Stampfuss, P. Censarek, J. W. Fischer, K. Schror, and A.-A. Weber
Rapid Release of Active Tissue Factor From Human Arterial Smooth Muscle Cells Under Flow Conditions
Arterioscler Thromb Vasc Biol,
May 1, 2006;
26(5):
e34 - e37.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Banerjee, J. Mizuguchi, S. Iwanaga, and R. M. Kini
Hemextin AB Complex, a Unique Anticoagulant Protein Complex from Hemachatus haemachatus (African Ringhals Cobra) Venom That Inhibits Clot Initiation and Factor VIIa Activity
J. Biol. Chem.,
December 30, 2005;
280(52):
42601 - 42611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Ramasethu
Management of Vascular Thrombosis and Spasm in the Newborn
NeoReviews,
June 1, 2005;
6(6):
e298 - e311.
[Full Text]
[PDF]
|
|
|
|
|
